双极性抑郁症中lumateperone的剂量反应疗效和安全性:随机对照试验的初步元分析
在PubMed上查看摘要
概括
此摘要是机器生成的。对于双极性抑郁症来说,42毫克的卢马特佩龙剂量是有前途的,改善了症状和生活质量. 然而,随着不良事件的增加,需要谨慎和进一步研究以获得最佳剂量.
科学领域
- 精神病学
- 药理学
- 临床研究
背景情况
- 治疗双极性抑郁症的最佳剂量尚未确定.
- 目前关于双极性抑郁症的有效性和安全性的数据需要进一步的剂量反应分析.
研究的目的
- 为了研究lumateperone在双极性抑郁症中的疗效和安全性.
- 系统地分析不同剂量对抑郁症严重程度,整体疾病,生活质量和不良事件的影响.
主要方法
- 在主要数据库中进行了系统的文献搜索,直到2025年7月.
- 在3项涉及1454名患者的随机对照试验中进行了剂量反应元分析.
- 疗效结果包括抑郁症的严重程度,整体疾病的严重程度,生活质量,反应率和缓解率. 安全结果包括与不良事件 (AE) 相关的中止,治疗出现的AE,躁狂,自杀倾向和代谢变化.
主要成果
- 卢马特佩龙每天42毫克显著改善了抑郁症状 (SMD=0. 26),全球双极性疾病严重程度 (SMD=0. 31),双极性抑郁症严重程度 (SMD=0. 33),生活质量 (SMD=0. 22),以及反应率 (RR=1. 27).
- 与安慰剂相比,由于不良事件 (AEs) 而导致的停药显著增加42mg剂量 (RR=3. 12),但28mg剂量并没有增加.
- 对于复发率,整体学率或其他安全结果,没有观察到显著的剂量反应趋势.
结论
- 初步证据表明,每天服用42毫克卢马特佩龙可能对双极性抑郁症具有临床益处.
- 在临床实践中需要仔细考虑42毫克剂量的AE相关停药率的增加.
- 需要进一步的研究来确定最佳的lumateperone剂量,以平衡双极性抑郁症的疗效和安全性.
相关概念视频
Mania, a psychological condition characterized by elevated mood, increased energy, and reduced sleep need, is part of the bipolar disorder cycle. The exact cause of mania isn't entirely known, but it is thought to be a combination of genetic, environmental, and neurological factors. Bipolar disorder involves alternating manic and depressive episodes. Mood stabilizers like lithium, antipsychotics, and anticonvulsants help manage these episodes. Lithium carbonate is particularly effective as...
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
The elimination half-life and drug clearance of drugs following nonlinear kinetics can vary with dosage. The Michaelis-Menten parameters and drug concentration influence these factors. As the dose increases, the elimination half-life tends to lengthen, resulting in a reduction in clearance and a disproportionately larger area under the curve. The total clearance can be derived from the Michaelis-Menten equation for drugs following a one-compartment model.
A study on guinea pigs examined the...
The potency of a drug is the measure of its ability to produce a biological response and can be compared by looking at the half-maximum effective concentration or EC50 values of different drugs. A lower EC50 value indicates higher potency of the drug. In the dose–response curve of two antihypertensive drugs, candesartan and irbesartan, a significant difference is observed in their EC50 values. A lower EC50 value for candesartan indicates that it is more potent than irbesartan, as it...
Electroconvulsive therapy (ECT), or shock therapy, remains a critical biomedical intervention for severe, treatment-resistant depression. While its origins can be traced back to Hippocrates' observations that malaria-induced convulsions alleviated mental illness, modern ECT has evolved significantly from its earlier, more primitive applications. First introduced in 1938 by Ugo Cerletti and his colleagues, ECT involves inducing controlled seizures using electrical currents. In its early...
Agonists can bind with and activate receptors, resulting in the formation of drug-receptor complexes. Once formed, these complexes catalyze many biochemical processes at the cellular level and subsequently induce a pharmacologic response. The degree of response is directly proportional to the fraction of activated receptors, which in turn, depends on the concentration of the drug at the receptor site as well as the sensitivity of the receptor. An increase in the administered dose contributes to...

